Trial: 201910006

A PHASE 1B/2 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND CLINICAL ACTIVITY OF EQ001 IN SUBJECTS WITH NEWLY DIAGNOSED ACUTE GRAFT VERSUS HOST DISEASE

Phase

I/II

Principal Investigator

Schroeder, Mark

Disease Site

Other Hematopoietic

Learn more about this study at: clinicaltrials.gov